Insights
Search Results
Newsletters
6.03.26
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Client Highlights
6.03.26
Wilson Sonsini Advises Luminopia on Licensing Agreement with ROHTO
On June 2, 2026, Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co., LTD, a Japanese multinational corporation specializing in consumer products and pharmaceuticals. Wilson Sonsini Goodrich & Rosati advised Luminopia on the transaction.
Client Highlights
4.14.26
Firm Advises Getlabs on Acquisition by Function
On April 8, 2026, Function Health announced it has acquired Getlabs, a leading mobile healthcare platform that brings licensed specialists directly to one's location. The acquisition allows for the continuation of Getlab’s nationwide network of providers, health systems, and partners, while advancing Function's broader commitment to making healthcare more accessible by building experiences around member needs. Wilson Sonsini Goodrich & Rosati advised Getlabs on the transaction.
Client Highlights
4.13.26
Wilson Sonsini Advises Ultralight on $9.3 Million Seed Funding
On April 13, 2026, Ultralight, the AI-native operating system for modern medicine, announced that it has raised $9.3 million in seed funding. The round was led by The General Partnership, with participation from Wisdom Ventures, Anthemis Group, Emerson Collective, GSBackers, and various angel investors. Wilson Sonsini Goodrich & Rosati advised Ultralight on the transaction.
Ultralight’s platform automates busywork, surfaces deep clinical insights, and frees clinicians to practice high-touch medicine. Designed for clinicians who lead functional, integrative, or longevity practices, Ultralight unifies electronic health records, practice management, and patient engagement in one vertical SaaS stack, with powerful AI natively built in.
The Wilson Sonsini team that advised Ultralight on the financing includes Lang Liu and Oliver Zhou.
For more information, please see Ultralight CEO Sunita Mohanty’s LinkedIn post and this Axios article.
Ultralight’s platform automates busywork, surfaces deep clinical insights, and frees clinicians to practice high-touch medicine. Designed for clinicians who lead functional, integrative, or longevity practices, Ultralight unifies electronic health records, practice management, and patient engagement in one vertical SaaS stack, with powerful AI natively built in.
The Wilson Sonsini team that advised Ultralight on the financing includes Lang Liu and Oliver Zhou.
For more information, please see Ultralight CEO Sunita Mohanty’s LinkedIn post and this Axios article.
Alerts
4.06.26
FTC Announcement of Healthcare Task Force Coincides with Joint DOJ/FTC Appearance at ONC Annual Meeting
Two recent developments suggest that enforcers are poised to grapple with antitrust concerns in health tech, signaling an escalation of scrutiny into Information Blocking1 tactics that have persisted despite U.S. Department of Health and Human Services (HHS) rules and regulations designed to curtail such practices. Stakeholders and industry participants should be prepared for potential outreach.
Client Highlights
4.02.26
Wilson Sonsini Advises View Point Medical on Acquisition by Merit Medical
On April 1, 2026, Merit Medical Systems, Inc., a global leader of healthcare technology, announced it has acquired View Point Medical, Inc. The aggregate transaction consideration, including the assumption of View Point liabilities, is approximately $140 million. Wilson Sonsini Goodrich & Rosati advised View Point on the transaction.
Client Highlights
3.24.26
Firm Advises Dimer Health on $13.5 Million Series A Financing
On March 23, 2026, Dimer Health, a clinician-led, AI-native transitional care medicine company, announced $13.5 million in Series A financing led by Team8 and Bill Ackman's Table Management, with participation from existing investors Silver Circle and TechAviv. The round brings the company's total funding to $20 million and will support national expansion of Dimer's dedicated post-discharge clinical service line, now operating across eight states. Wilson Sonsini Goodrich & Rosati advised Dimer on the transaction.
Client Highlights
3.10.26
Wilson Sonsini Advises Sandbar on $23 Million Series A
On March 10, 2026, New York City-based Sandbar, an AI-enabled wearables company, announced it has raised $23 million in a Series A funding round led by Adjacent and Kindred Ventures, bringing total funding to $36 million. Wilson Sonsini Goodrich & Rosati advised Sandbar on the transaction.
Client Highlights
2.10.26
Firm Advises IVP as Lead Investor in Solace Health’s $130 Million Series C
On February 10, 2026, Solace Health announced a $130 million Series C funding round led by IVP, accelerating the company’s mission to make advocacy a standard part of care for every patient in the United States. The Series C values Solace at over $1 billion and reflects growing consensus that healthcare advocacy is no longer optional as costs rise and systems fracture. Wilson Sonsini Goodrich & Rosati advised IVP on the transaction.
The round also included participation from existing investors Menlo Ventures, SignalFire, Torch Capital, Inspired Capital, and RiverPark Ventures. With this funding, Solace will significantly expand its national network of more than 2,000 experienced advocates serving Medicare and Medicare Advantage members, while accelerating investment in its platform and clinical research. The company will also deepen partnerships with payers and providers to embed advocacy earlier in the care journey where outcomes are most at risk.
The Wilson Sonsini team that advised IVP on the transaction included Becki DeGraw, Madeleine Vella, Andrea Linna, Nawa Lodin, Chris Paniewski, Isabel Annino, and Daniel Chen.
For more information, please see Solace Health’s news release. Additional coverage is available on Fierce Healthcare and MedCity News.
The round also included participation from existing investors Menlo Ventures, SignalFire, Torch Capital, Inspired Capital, and RiverPark Ventures. With this funding, Solace will significantly expand its national network of more than 2,000 experienced advocates serving Medicare and Medicare Advantage members, while accelerating investment in its platform and clinical research. The company will also deepen partnerships with payers and providers to embed advocacy earlier in the care journey where outcomes are most at risk.
The Wilson Sonsini team that advised IVP on the transaction included Becki DeGraw, Madeleine Vella, Andrea Linna, Nawa Lodin, Chris Paniewski, Isabel Annino, and Daniel Chen.
For more information, please see Solace Health’s news release. Additional coverage is available on Fierce Healthcare and MedCity News.
Client Highlights
2.05.26
Wilson Sonsini Advises Fair Square Medicare on Acquisition by Senior Market Sales
On January 30, 2026, Senior Market Sales®(SMS), one of the industry’s premier insurance marketing organizations (IMOs), announced that it has acquired Fair Square Medicare, a technology-driven health care platform designed to simplify the Medicare experience for seniors. This strategic acquisition enhances SMS’ suite of digital tools and reinforces its commitment to providing guidance to seniors as they navigate Medicare coverage. Wilson Sonsini Goodrich & Rosati advised Fair Square on the transaction.